Publication Name	World Journal of Diabetes
Manuscript ID	100533
Country	China

Received	2024-08-20 06:21
Peer-Review Started	2024-09-06 00:47
To Make the First Decision
Return for Revision	2024-12-24 03:52
Revised	2024-12-30 02:36
Second Decision	2025-01-10 02:35
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2025-01-10 07:27
Articles in Press	2025-01-10 07:27
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2025-01-31 08:03
Publish the Manuscript Online	2025-02-28 10:45

ISSN	1948-9358 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Endocrinology & Metabolism
Manuscript Type	Letter to the Editor
Article Title	Exploration of metformin-based drug combination for mitigating diabetes-associated atherosclerotic diseases
Manuscript Source	Invited Manuscript
All Author List	Biao Qu, Zheng Li and Wei Hu
ORCID	Author(s) ORCID Number Zheng Li http://orcid.org/0000-0002-2882-6600 Wei Hu http://orcid.org/0000-0002-4809-7601
Funding Agency and Grant Number	Funding Agency Grant Number the Natural Science Research Project of Anhui Province 2023AH053172 National Natural Science Foundation of Anhui Province 2408085QH260 Projects of Administration of Traditional Chinese Medicine of Anhui Province 2024CCCX082 National Natural Science Foundation Incubation Program of The Second Hospital of Anhui Medical University 2022GMFY08
Corresponding Author	Wei Hu, PhD, Professor, Department of Clinical Pharmacology, The Second Hospital of Anhui Medical University, No. 678 Furong Road, Hefei 230601, Anhui Province, China. huwei@ahmu.edu.cn
Key Words	Diabetes; Atherosclerotic diseases; Metformin; Drug combination; Hypoglycemic agent; Hypolipidemic agent; Antioxidant agent
Core Tip	The hyperglycemic state can actually induce atherosclerosis development or further accelerate its progression, which leads to cardio-cerebrovascular diseases associated with high morbidity and mortality. As metformin is the preferred first-line drug to manage type 2 diabetes, metformin combined with either hypoglycemic agents, hypolipidemic agents, or systemic antioxidant/anti-inflammatory agents, have been investigated to provide additional vascular benefits. It is quite clear that such exploration can contribute to finding a better drug combination to mitigate diabetes-associated atherosclerotic diseases.
Publish Date	2025-02-28 10:45
Citation	<p>Qu B, Li Z, Hu W. Exploration of metformin-based drug combination for mitigating diabetes-associated atherosclerotic diseases. <i>World J Diabetes</i> 2025; 16(4): 100533</p>
URL	https://www.wjgnet.com/1948-9358/full/v16/i4/100533.htm
DOI	https://dx.doi.org/10.4239/wjd.v16.i4.100533

Full Article (PDF)	WJD-16-100533-with-cover.pdf
Manuscript File	100533_Auto_Edited_011629.docx
Answering Reviewers	100533-answering-reviewers.pdf
Audio Core Tip	100533-audio.m4a
Conflict-of-Interest Disclosure Form	100533-conflict-of-interest-statement.pdf
Copyright License Agreement	100533-copyright-assignment.pdf
Approved Grant Application Form(s) or Funding Agency Copy of any Approval Document(s)	100533-foundation-statement.pdf
Non-Native Speakers of English Editing Certificate	100533-non-native-speakers.pdf
Peer-review Report	100533-peer-reviews.pdf
Scientific Misconduct Check	100533-scientific-misconduct-check.png
Scientific Editor Work List	100533-scientific-editor-work-list.pdf
CrossCheck Report	100533-crosscheck-report.png
CrossCheck Report	100533-crosscheck-report.pdf